ecDNA elements have been recognized for over half a century, first described in the mid-1960s through cytogenetic analyses that revealed chromosomal fragments forming circular DNA structures independent of the main chromosomal genome. The clinical significance of ecDNA came into sharper focus in the late 1970s when mouse models demonstrated their role in mediating resistance to chemotherapeutic agents. Since then, mounting evidence highlights that ecDNA are disproportionately abundant in aggressive cancers, where they frequently amplify oncogenes—genes that can transform a normal cell into a tumor cell when overexpressed or mutated. The spatial dislocation from chromosomes endows ecDNA with unique regulatory freedoms, enabling dynamic gene expression that fuels cancer cell adaptability and malignancy.

Dr. Lukas Chavez, a leading scientist specializing in the cancer genome and epigenetics at Sanford Burnham Prebys, underscores the clinical gravity of ecDNA presence in tumors. “The presence of these extrachromosomal DNA loops correlates strongly with worsened patient outcomes, underscoring their potential as both biomarkers and therapeutic targets,” Chavez explains. However, a pressing gap persisted in the field regarding the fidelity of PDX models to faithfully replicate the ecDNA landscape observed in original human tumors. Addressing this gap is critical because the utility of PDX models hinges on their ability to mirror human tumor biology as closely as possible.

To investigate this, the research team undertook a comprehensive analysis of nearly 300 pediatric tumor samples representing over 30 cancer types alongside their corresponding PDX models. Using high-resolution genomic sequencing techniques, they meticulously cataloged ecDNA elements, focusing on copy number variations of oncogenes carried extrachromosomally. The findings were striking—ecDNA were detected in approximately one-third of the tumor samples, reflecting a significant burden in pediatric oncology. Importantly, the oncogene amplification profiles on ecDNA matched those documented in large-scale cancer genomics datasets, reaffirming the clinical relevance of their observations.

A particularly compelling aspect of the study involved comparative genome sequencing of paired human tumors and their PDX counterparts. In over 80% of pairs, ecDNA presence was directly concordant, and the ecDNA sequences themselves were substantially preserved. This genomic fidelity implies that PDX models not only retain the structural features of ecDNA but also maintain the oncogenic potential encoded therein. These data provide robust evidence that PDX models are valid surrogates for studying ecDNA-driven biology in pediatric brain and other cancers.

Beyond bulk genomic analyses, the team harnessed single-cell sequencing technologies to dissect ecDNA distribution at the cellular level within tumors and PDX models. In one tumor-PDX pair, an overwhelming majority of cells contained ecDNA, suggesting a dominant clone driving tumorigenesis. Remarkably, another pair exhibited ecDNA only in a small fraction of tumor cells, yet the derived PDX model showed ecDNA presence in nearly all cells. This finding implies that ecDNA-positive cells possess a selective growth advantage during PDX development, potentially mirroring clonal expansion patterns in vivo.

These observations offer critical insights into tumor heterogeneity and clonal evolution, highlighting ecDNA as a molecular driver that shapes tumor architecture and treatment resistance. Given that ecDNA can dynamically modulate oncogene dosage and gene expression, their selective proliferation in PDX models reinforces the validity of these systems for therapeutic testing. Moreover, the research supports the notion that targeting ecDNA mechanisms, such as their replication or segregation during cell division, could open new avenues for combating aggressive, treatment-resistant cancers.

Looking ahead, the research consortium plans to employ PDX models to longitudinally track ecDNA evolution in response to conventional therapies, including chemotherapy and radiation. By elucidating how ecDNA facilitates cellular adaptation and survival under therapeutic pressure, scientists aim to identify vulnerabilities that can be exploited for more effective interventions. Such efforts could pave the way for precision medicine strategies tailored to the unique ecDNA landscape of individual tumors.

“Our primary goal is to deepen our understanding of ecDNA-mediated treatment resistance and uncover novel therapeutic targets that can improve outcomes for children battling these devastating cancers,” says Dr. Chavez. The study’s insights into the molecular fidelity of PDX models mark a crucial step toward this goal, providing researchers with robust tools to interrogate the complexities of cancer genome plasticity.

This research was made possible through the collaborative efforts of scientists from Sanford Burnham Prebys, Nagoya City University, the University of California San Diego, Rady Children’s Hospital, and Columbia University Irving Medical Center. Supported by prominent funding bodies, including the National Institutes of Health, National Cancer Institute, National Science Foundation, and several foundations dedicated to cancer research, the study epitomizes the power of interdisciplinary collaboration in advancing pediatric oncology.

In sum, this landmark study not only validates the use of PDX models for studying extrachromosomal DNA in childhood cancers but also heralds a new era of targeted therapeutic exploration. As the field evolves, leveraging such models to decode the role of ecDNA in treatment resistance and tumor evolution promises to transform pediatric cancer management, offering hope for more durable remissions and cures.

Subject of Research: Animals

Article Title: Preservation and clonal behavior of extrachromosomal DNA in patient-derived xenograft models of childhood cancers

News Publication Date: 28-May-2026

Web References:

• https://doi.org/10.1186/s13073-026-01676-0
• https://link.springer.com/article/10.1186/s13073-026-01676-0

Image Credits: Sanford Burnham Prebys

Keywords: Cancer, Brain cancer, Oncogenes, Cancer research, Cancer genomics, Genomics, Cancer genome sequencing, Cancer proliferation genes, Tumor suppressors, Single cell sequencing

PDX models originate by engrafting freshly resected human tumor specimens directly into immunodeficient murine hosts. This method preserves the heterogeneity of tumor genetics, the intricate tumor microenvironment, and dynamic drug responsiveness that traditional cell line models fail to capture. Cell lines often lose critical tumor-specific features through prolonged in vitro culture, but PDXs maintain the malignant phenotype in vivo, providing a more faithful and clinically relevant experimental framework. Consequently, PDX models have emerged as an indispensable asset for investigating novel therapeutic strategies prior to clinical trials.

Crucially, PDX models permit the conduct of co-clinical trials, a revolutionary approach where patients receive treatment concurrently with their personalized PDX avatars. This parallel testing enables real-time assessment of therapeutic efficacy, facilitating rapid adaptation of clinical interventions tailored for individual patients. By integrating clinical decision-making with rigorous preclinical validation, this strategy advances the precision medicine vision from concept to clinical application. Notably, PDX models have already yielded critical insights in breast, lung, colorectal, and ovarian cancers, among other malignancies.

Despite their promise, PDX models confront substantial hurdles that have limited their widespread adoption. The complexity of establishing such models demands high costs and extended engraftment periods, requiring access to specialized animal facilities and skilled personnel. Additionally, genetic and epigenetic drift can occur within the murine host, potentially diverging from the evolution observed in patient tumors over time. This discrepancy poses challenges for modeling long-term disease progression and resistance mechanisms, necessitating ongoing efforts to refine system fidelity.

To transcend current limitations, innovative next-generation PDX platforms are under development. Integrating cutting-edge technologies like CRISPR-Cas9 gene editing allows for precise manipulation of tumor genomes within PDXs, enabling in-depth functional studies of oncogenic drivers and resistance pathways. Coupling PDX models with organoid co-cultures offers a hybrid system to examine tumor-stroma interactions and drug responses ex vivo while maintaining physiological relevance. Furthermore, humanized mouse models, equipped with reconstituted human immune systems, provide powerful tools for evaluating immunotherapy responses within the PDX framework.

Biobanking of patient-derived tumors coupled with artificial intelligence-driven analytics is accelerating PDX model utility. High-throughput sequencing and machine learning algorithms facilitate comprehensive characterization of PDX molecular profiles, predicting therapeutic vulnerabilities with unprecedented accuracy. These advances not only expedite drug discovery and validation but also enable stratified medicine approaches that select optimal therapies based on tumor-specific signatures captured by PDX models. Such integration is poised to reshape oncological drug development paradigms fundamentally.

Another advantage of PDX systems lies in their ability to test combination therapies and adaptive dosing regimens in a highly personalized context. By recapitulating patient-specific tumor biology, PDXs allow researchers to dissect mechanistic pathways driving therapeutic synergy or resistance. This capability is invaluable for developing next-generation regimens that circumvent resistance mechanisms and enhance durable responses. The fine-tuned modeling of interpatient variability enhances the translational relevance of PDX-derived data, informing clinical trial design more effectively.

However, ethical considerations and logistical constraints still pose barriers to PDX model scalability. The reliance on immunodeficient rodents warrants careful consideration of welfare and reduction strategies in animal research. Advances in three-dimensional culture systems and in silico modeling may eventually complement or, in part, replace PDX usage, but for now, PDXs remain unparalleled in their predictive power for human oncological applications. Continued investment in infrastructure and collaborative frameworks is essential to democratize access to these powerful models in the research community.

Furthermore, the heterogeneity of tumor microenvironments within PDXs underscores the importance of careful experimental design and interpretation. Infiltrating stromal cells and vasculature components derive from host murine tissue, which can influence tumor behavior and therapeutic responses differently from the native human microenvironment. Addressing this issue through humanization protocols or co-implantation strategies is a fertile area of ongoing research, aiming to recreate a more authentic tumor niche and improve translational validity.

In light of mounting evidence, the role of PDX models as a cornerstone of precision oncology is increasingly apparent. As cancer biology research confronts the multifaceted nature of malignancies, PDX systems offer unparalleled opportunities for dissecting tumor complexity and tailoring therapeutic interventions. Given their ability to bridge experimental findings with clinical realities, these models are set to become standard tools in oncological research, drug development pipelines, and personalized patient care algorithms worldwide.

The convergence of emerging genomic editing technologies, immune-oncology advancements, and computational biology ensures that PDX models will evolve rapidly to meet future challenges. By embracing these multifaceted innovations, researchers are positioning PDX platforms not only as experimental stand-ins but as predictive engines fueling next-generation cancer therapies. Through this lens, the dynamic landscape of cancer precision medicine will be sharpened significantly, ultimately improving patient outcomes and survival rates.

As the oncology community moves forward, continued collaboration between clinicians, basic researchers, and biotechnology developers will be critical in harnessing the full potential of PDX models. Investing in the optimization, standardization, and dissemination of these models globally will accelerate translational breakthroughs. Together, these coordinated efforts herald a new era where cancer treatment becomes increasingly personalized, efficient, and successful—a testament to the power of patient-derived xenograft models in revolutionizing cancer therapeutics.

Subject of Research:
Patient-derived xenograft (PDX) models in cancer research and their role in precision oncology.

Article Title:
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research

News Publication Date:
2025

References:
Minqi Liu, Xiaoping Yang, Patient-derived xenograft models: Current status, challenges, and innovations in cancer research, Genes & Diseases, Volume 12, Issue 5, 2025, 101520.

Image Credits:
Genes & Diseases

Keywords:
Cancer genetics, patient-derived xenograft models, precision medicine, drug resistance, tumor microenvironment, CRISPR gene editing, humanized mouse models, organoid co-cultures, co-clinical trials, biobanking, artificial intelligence in drug discovery, immuno-oncology.